Gemtuzumab ozogamicin – Uses, Dosage, Side Effects, Interation

Gemtuzumab ozogamicin is a monoclonal anti-CD33 antibody used to treat CD33-positive acute myeloid leukemia. Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody that is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. catechesis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles of calicheamicin per mole of antibody. The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML). By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death.

Marketing approval of gemtuzumab ozogamicin was granted on May 17, 2000, by FDA as a treatment for patients with CD33-positive AML in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy ^[rx]. However, it was voluntarily withdrawn from the market in 2010 due to safety concerns, increased patient deaths, and insufficient evidence of clinical benefit during confirmatory trials ^[rx]. On September 1, 2017, gemtuzumab ozogamicin was again approved for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia but with a lower dosing regimen and a different schedule in combination with chemotherapy or on its own ^[rx]. It is also indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory) ^[rx].

Mechanism of action

Mylotarg is directed against the CD33 antigen expressed by hematopoietic cells. Binding of the anti-CD33 antibody portion of Mylotarg with the CD33 antigen results in the formation of a complex that is internalized. Upon internalization, the calicheamicin derivative is released inside the lysosomes of the myeloid cell. The released calicheamicin derivative binds to DNA in the minor groove resulting in site-specific DNA double-strand breaks via the formation of a p-benzene diradical ⁴. Eventually, cell death is induced.

Used for the treatment of acute myeloid leukemia (AML), Mylotarg binds to the CD33 antigen, which is expressed on the surface of leukemic cells in more than 80% of patients with AML. The CD33 antigen is not expressed on pluripotent hematopoietic stem cells or nonhematopoietic cells. This gives Mylotarg the selectivity needed to target leukemic cells.

or

Gemtuzumab ozogamicin is a CD33-directed antibody-drug conjugate (ADC). The antibody portion (hP67.6) recognizes human CD33 antigen. The small molecule, N-acetyl gamma calicheamicin, is a cytotoxic agent that is covalently attached to the antibody via a linker. Nonclinical data suggest that the anticancer activity of gemtuzumab ozogamicin is due to the binding of the ADC to CD33-expressing tumor cells, followed by internalization of the ADC-CD33 complex, and the intracellular release of N-acetyl gamma calicheamicin dimethyl hydrazide via hydrolytic cleavage of the linker. Activation of N-acetyl gamma calicheamicin dimethyl hydrazide induces double-strand DNA breaks, subsequently inducing cell cycle arrest and apoptotic cell death.

Indications

• Indicated for the treatment of patients with CD33-positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy. Indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory).
• Acute Myeloid Leukemia (AML)
• Refractory Acute Myeloid Leukemia (AML)
• Relapsed Acute Myelogenous Leukemia (AML)

Use in Cancer

Gemtuzumab ozogamicin is approved to treat:

• Acute myeloid leukemia that is CD33 positive.
  • It is used in adults and children aged 1 month and older with the newly-diagnosed diseases.
  • It is used in adults and children aged 2 years and older whose disease has relapsed or is refractory (does not respond to treatment).

Gemtuzumab ozogamicin is also being studied in the treatment of other types of cancer.

Contraindications

• low amount of magnesium in the blood
• low amount of calcium in the blood
• low amount of potassium in the blood
• decreased blood platelets
• low levels of a type of white blood cell called neutrophils
• abnormal EKG with QT changes from birth
• hepatic veno-occlusive disease, a type of liver disease
• liver problems
• pregnancy
• a patient who is producing milk and breastfeeding

Dosage

Strengths: 4.5 mg

Acute Myeloid Leukemia

Newly diagnosed CD33-positive acute myeloid leukemia (AML):
COMBINATION REGIMEN (therapy consists of 1 induction cycle and 2 consolidation cycles in combination with chemotherapy):

• Induction: 3 mg/m2 (maximum 4.5 mg/dose) IV over 2 hours on Days 1, 4, and 7 in combination with daunorubicin and cytarabine (for patients who require a second induction cycle, gemtuzumab is NOT given during the second induction cycle)
• Consolidation (2 cycles): 3 mg/m2 (maximum 4.5 mg/dose) IV over 2 hours on Day 1 in combination with daunorubicin and cytarabine

Newly diagnosed CD33-positive acute myeloid leukemia (AML):
SINGLE AGENT REGIMEN (MONOTHERAPY) (therapy consists of 1 induction cycle and up to 8 continuation cycles):

• Induction: 6 mg/m2 IV over 2 hours on Day 1 and 3 mg/m2 IV on Day 8
• Continuation: 2 mg/m2 IV over 2 hours on Day 1 every 4 weeks

Relapsed or Refractory CD33-positive AML:
SINGLE-AGENT REGIMEN (MONOTHERAPY):

• 3 mg/m2 (maximum 4.5 mg/dose) IV over 2 hours on Days 1, 4, and 7
• Treatment in the relapsed or refractory setting consists of a single course of gemtuzumab.
• Premedicate with acetaminophen 650 mg orally and diphenhydramine 50 mg orally or IV one hour prior to infusion, and methylprednisolone (or equivalent) 1 mg/kg orally or IV within 30 minutes prior to infusion. Repeat the same dose of methylprednisolone (or equivalent) for any sign of an infusion reaction (e.g., fever, chills, hypotension, dyspnea) during the infusion or within 4 hours of the infusion.
• Monitor vital signs during infusion and for 4 hours following infusion.
• For patients with hyperleukocytosis (leukocyte count greater than or equal to 30 Gi/L), cytoreduction is recommended prior to the administration of this drug.
• For newly diagnosed CD33-positive acute myeloid leukemia (AML)
• For relapsed or refractory CD33-positive AML

Acute Myeloid Leukemia

Newly Diagnosed De Novo CD33-positive AML (Combination Regimen):
ONE MONTH AND OLDER:

• Body surface area (BSA) less than 0.6 m2: 0.1 mg/kg IV over 2 hours
• BSA 0.6 m2 or greater: 0.3 mg/m2 IV over 2 hours

INDUCTION 1:

• For Induction 1, gemtuzumab is given once in combination with standard chemotherapy; no gemtuzumab is given in the second induction cycle.

INTENSIFICATION:

• No gemtuzumab is given in the first or third intensification cycles; for Intensification 2, gemtuzumab is given once in combination with standard chemotherapy; consider the risks and potential benefits before giving gemtuzumab during Intensification 2.

Relapsed or Refractory CD33-positive AML:
SINGLE-AGENT REGIMEN (MONOTHERAPY):
2 YEARS AND OLDER:
3 mg/m2 (maximum 4.5 mg/dose) IV over 2 hours on Days 1, 4, and 7

• Treatment in the relapsed or refractory setting consists of a single course of gemtuzumab.
• Premedicate children 1 month and older with acetaminophen 15 mg/kg (maximum of 650 mg) orally and diphenhydramine 1 mg/kg (maximum of 50 mg) orally or IV within 1 hour of infusion, and methylprednisolone 1 mg/kg orally or IV within 30 minutes of infusion. Additional doses of acetaminophen and diphenhydramine may be administered every 4 hours if needed. Repeat with the same dose of methylprednisolone (or equivalent) for an infusion reaction (e.g., fever, chills, hypotension, dyspnea) during the infusion or within 4 hours of the infusion.
• Monitor vital signs during infusion and for 4 hours following infusion.
• For patients with hyperleukocytosis (leukocyte count greater than or equal to 30 Gi/L), cytoreduction is recommended prior to the administration of this drug.
• For the treatment of newly diagnosed CD33-positive acute myeloid leukemia in pediatric patients 1 month and older
• For relapsed or refractory CD33-positive acute myeloid leukemia (AML) in pediatric patients 2 years and older

Dose Adjustments

FOR PATIENTS RECEIVING GEMTUZUMAB IN COMBINATION THERAPY:
PERSISTENT THROMBOCYTOPENIA:

• ADULTS: If platelet count does not recover to greater than or equal to 100 Gi/L within 14 days following the planned start date of the consolidation cycle (14 days after hematologic recovery following the previous cycle), discontinue gemtuzumab (do not administer gemtuzumab in the consolidation cycles).
• PEDIATRICS: Patients should have a platelet count of 75 Gi/L before the next cycle (induction or intensification).

PERSISTENT NEUTROPENIA:

• ADULTS: If the neutrophil count does not recover to greater than 0.5 Gi/L within 14 days following the planned start date of the consolidation cycle (14 days after hematologic recovery following the previous cycle), discontinue gemtuzumab (do not administer gemtuzumab in the consolidation cycles).
• PEDIATRICS: Patients should have a neutrophil count of 1 Gi/L before the next cycle (induction or intensification).

FOR ALL PATIENTS RECEIVING GEMTUZUMAB (MONOTHERAPY OR COMBINATION THERAPY:
VENO-OCCLUSIVE LIVER DISEASE (VOD):

• Manage hepatic toxicity by dose interruption or discontinuation of therapy.
• In patients who experience VOD, discontinue therapy and treatment according to standard medical practice.

INFUSION-RELATED REACTIONS:

• Interrupt the infusion and manage medically.
• Administer acetaminophen, diphenhydramine, and/or methylprednisolone, if needed. Provide supportive care as needed.
• For mild, moderate, or severe infusion-related reactions, once symptoms resolve, consider resuming the infusion at no more than one-half the rate at which the reaction occurred.
• Repeat the procedure in the event of a recurrence of symptoms.
• Permanently discontinue therapy upon the occurrence of a severe infusion reaction or for any life-threatening infusion reaction.

OTHER SEVERE OR LIFE-THREATENING NONHEMATOLOGIC TOXICITIES:

• Delay therapy until recovery to a severity of no more than mild.
• Omit scheduled dose if delayed more than 2 days between sequential infusions.

Administration advice:

• Use an in-line 0.2-micron polyethersulfone (PES) filter for infusion.
• Protect the IV bag from light using a light-blocking cover during the infusion. The infusion line does not need to be protected from light.
• Infuse the diluted solution over 2 hours.

Side Effects

The Most Common

• rash
• diarrhea
• constipation
• nausea
• vomiting
• headache
• pain
• pain, swelling, or sores in mouth or throat
• unusual or severe bleeding or bruising
• cough, shortness of breath, or difficulty breathing
• fast heartbeat
• fever, chills, sore throat, or other signs of infection

More common

• Bleeding gums
• blood in the urine or stools
• blurred vision
• bone pain
• chest pain
• chills
• confusion
• cough
• coughing up blood
• decreased urine output
• difficulty in breathing or swallowing
• dizziness, lightheadedness, or fainting
• dry mouth
• fast or irregular heartbeat
• fever
• flushed, dry skin
• fruit-like breath odor
• headache
• hoarseness
• increased hunger
• increased menstrual flow or vaginal bleeding
• increased thirst
• increased urination
• irregular heartbeat
• loss of appetite
• loss of consciousness
• lower back or side pain
• mood changes
• muscle pain or cramps
• nausea
• nosebleeds
• numbness or tingling in the hands, feet, or lips
• painful or difficult urination
• paralysis
• pinpoint red spots on the skin
• prolonged bleeding from cuts
• rapid, shallow breathing
• rash
• red or black, tarry stools
• red or dark brown urine
• seizures
• sore throat
• stomach pain and bloating
• sweating
• swelling of the face, ankles, or hands
• tightness in the chest
• unexplained weight loss
• unusual bleeding or bruising
• unusual tiredness or weakness
• vomiting

Rare

• Blue lips and fingernails
• coughing that sometimes produces a pink frothy sputum
• difficult, fast, noisy breathing
• fast, pounding, or irregular heartbeat or pulse
• increased sweating
• pale skin
• ulcers, sores, or white spots in the mouth
• Stomach cramps
• watery or bloody diarrhea

Drug Interactions

DRUG	INTERACTION
Abatacept	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Abatacept.
Abciximab	The risk or severity of bleeding can be increased when Abciximab is combined with Gemtuzumab ozogamicin.
Acenocoumarol	The risk or severity of bleeding can be increased when Acenocoumarol is combined with Gemtuzumab ozogamicin.
Acetylsalicylic acid	The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Gemtuzumab ozogamicin.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Gemtuzumab ozogamicin.
Adenovirus type	The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Gemtuzumab ozogamicin.
Aducanumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Aducanumab.
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Gemtuzumab ozogamicin.
Alefacept	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Alefacept.
Alemtuzumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Alemtuzumab.
Alirocumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Alirocumab.
Allogeneic	The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Gemtuzumab ozogamicin.
Allopurinol	The risk or severity of adverse effects can be increased when Allopurinol is combined with Gemtuzumab ozogamicin.
Alteplase	The risk or severity of bleeding can be increased when Alteplase is combined with Gemtuzumab ozogamicin.
Altretamine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Altretamine.
Amivantamab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Amivantamab.
Amsacrine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Amsacrine.
Anagrelide	The risk or severity of bleeding can be increased when Anagrelide is combined with Gemtuzumab ozogamicin.
Anakinra	The risk or severity of adverse effects can be increased when Anakinra is combined with Gemtuzumab ozogamicin.
Ancrod	The risk or severity of bleeding can be increased when Ancrod is combined with Gemtuzumab ozogamicin.
Anifrolumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Anifrolumab.
Anistreplase	The risk or severity of bleeding can be increased when Anistreplase is combined with Gemtuzumab ozogamicin.
Ansuvimab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ansuvimab.
Anthrax immune	The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Gemtuzumab ozogamicin.
Anthrax vaccine	The risk or severity of infection can be increased when Anthrax vaccine is combined with Gemtuzumab ozogamicin.
Antilymphocyte	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Antilymphocyte immunoglobulin (horse).
Antithrombin Alfa	The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Gemtuzumab ozogamicin.
Antithrombin	The risk or severity of bleeding can be increased when Antithrombin III human is combined with Gemtuzumab ozogamicin.
Antithymocyte	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Antithymocyte immunoglobulin (rabbit).
Apixaban	The risk or severity of bleeding can be increased when Apixaban is combined with Gemtuzumab ozogamicin.
Apremilast	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Apremilast.
Ardeparin	The risk or severity of bleeding can be increased when Ardeparin is combined with Gemtuzumab ozogamicin.
Argatroban	The risk or severity of bleeding can be increased when Argatroban is combined with Gemtuzumab ozogamicin.
Arsenic trioxide	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Arsenic trioxide.
Articaine	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Articaine.
Asfotase alfa	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Asfotase alfa.
ACOVID-19 Vaccine	The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.
Atezolizumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Atezolizumab.
Atoltivimab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Atoltivimab.
Avelumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Avelumab.
Azacitidine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Azacitidine.
Azathioprine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Azathioprine.
Bacillus	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Gemtuzumab ozogamicin.
Bacillus antigen	The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Gemtuzumab ozogamicin.
Bacillus calmette	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Gemtuzumab ozogamicin.
Bamlanivimab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bamlanivimab.
Baricitinib	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Baricitinib.
Basiliximab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Basiliximab.
BCG vaccine	The risk or severity of infection can be increased when BCG vaccine is combined with Gemtuzumab ozogamicin.
Beclomethasone	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Beclomethasone dipropionate.
Belantamab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belantamab mafodotin.
Belatacept	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belatacept.
Belimumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belimumab.
Belinostat	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belinostat.
Belumosudil	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belumosudil.
Bemiparin	The risk or severity of bleeding can be increased when Bemiparin is combined with Gemtuzumab ozogamicin.
Bendamustine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bendamustine.
Bendroflumethiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Gemtuzumab ozogamicin.
Benralizumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Benralizumab.
Benzocaine	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Benzocaine.
Benzthiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Gemtuzumab ozogamicin.
Benzyl alcohol	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Benzyl alcohol.
Besilesomab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Besilesomab.
Betamethasone	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Betamethasone.
Betrixaban	The risk or severity of bleeding can be increased when Betrixaban is combined with Gemtuzumab ozogamicin.
Bevacizumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bevacizumab.
Bexarotene	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bexarotene.
Bezlotoxumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bezlotoxumab.
Bimekizumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bimekizumab.
Bivalirudin	The risk or severity of bleeding can be increased when Bivalirudin is combined with Gemtuzumab ozogamicin.
Bleomycin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bleomycin.
Blinatumomab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Blinatumomab.
Bordetella	The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Bortezomib	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bortezomib.
Bosutinib	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bosutinib.
Brentuximab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Brentuximab vedotin.
Brodalumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Brodalumab.
Brolucizumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Brolucizumab.
Budesonide	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Budesonide.
Bupivacaine	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Bupivacaine.
Burosumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Burosumab.
Busulfan	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Busulfan.
Butacaine	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Butacaine.
Butamben	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Butamben.
Cabazitaxel	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cabazitaxel.
Canakinumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Canakinumab.
Cangrelor	The risk or severity of bleeding can be increased when Cangrelor is combined with Gemtuzumab ozogamicin.
Capecitabine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Capecitabine.
Caplacizumab	The risk or severity of bleeding can be increased when Caplacizumab is combined with Gemtuzumab ozogamicin.
Capromab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Capromab pendetide.
Capsaicin	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Capsaicin.
Carbamazepine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carbamazepine.
Carboplatin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carboplatin.
Carfilzomib	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carfilzomib.
Carmustine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carmustine.
Casirivimab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Casirivimab.
Catumaxomab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Catumaxomab.
Cemiplimab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cemiplimab.
Certolizumab pegol	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Certolizumab pegol.
Cetuximab	The risk or severity of adverse effects can be increased when Cetuximab is combined with Gemtuzumab ozogamicin.

Chlorambucil	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Chlorambucil.
Chloramphenicol	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Chloramphenicol.
Chloroprocaine	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Chloroprocaine.
Chlorothiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Gemtuzumab ozogamicin.
Ciclesonide	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ciclesonide.
Cilgavimab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cilgavimab.
Cilostazol	The risk or severity of bleeding can be increased when Cilostazol is combined with Gemtuzumab ozogamicin.
Cinchocaine	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Cinchocaine.
Cisplatin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cisplatin.
Cladribine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cladribine.
Clobetasol	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Clobetasol propionate.
Clofarabine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Clofarabine.
Clopidogrel	The risk or severity of bleeding can be increased when Clopidogrel is combined with Gemtuzumab ozogamicin.
Clostridium	The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Clozapine	The risk or severity of neutropenia can be increased when Gemtuzumab ozogamicin is combined with Clozapine.
Cocaine	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Cocaine.
Cestrogens	Conjugated estrogens may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Corticotropin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Corticotropin.
Cortisone acetate	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cortisone acetate.
Corynebacterium	The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Cyanocobalamin	The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Gemtuzumab ozogamicin.
Cyclopenthiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Gemtuzumab ozogamicin.
Cyclophosphamide	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cyclophosphamide.
Cyclosporine	Gemtuzumab ozogamicin may increase the immunosuppressive activities of Cyclosporine.
Cyclothiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Gemtuzumab ozogamicin.
Cytarabine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cytarabine.
Dabigatran	The risk or severity of bleeding can be increased when Dabigatran is combined with Gemtuzumab ozogamicin.
Dabigatran	The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Gemtuzumab ozogamicin.
Dacarbazine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dacarbazine.
Dactinomycin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dactinomycin.
Dalteparin	The risk or severity of bleeding can be increased when Dalteparin is combined with Gemtuzumab ozogamicin.
Danaparoid	The risk or severity of bleeding can be increased when Danaparoid is combined with Gemtuzumab ozogamicin.
Daratumumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Daratumumab.
Darbepoetin alfa	The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Gemtuzumab ozogamicin.
Dasatinib	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dasatinib.
Daunorubicin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Daunorubicin.
Decitabine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Decitabine.
Defibrotide	The risk or severity of bleeding can be increased when Defibrotide is combined with Gemtuzumab ozogamicin.
Deflazacort	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Deflazacort.
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Gemtuzumab ozogamicin.
Desirudin	The risk or severity of bleeding can be increased when Desirudin is combined with Gemtuzumab ozogamicin.
Desoximetasone	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Desoximetasone.
Deucravacitinib	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Deucravacitinib.
Dexamethasone	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dexamethasone.
Dexrazoxane	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dexrazoxane.
Dextran	The risk or severity of bleeding can be increased when Dextran is combined with Gemtuzumab ozogamicin.
Dicoumarol	The risk or severity of bleeding can be increased when Dicoumarol is combined with Gemtuzumab ozogamicin.
Dienestrol	Dienestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Diethylstilbestrol	Diethylstilbestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Difluocortolone	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Difluocortolone.
Digoxin Immune	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Digoxin Immune Fab (Ovine).
Dimethyl fumarate	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dimethyl fumarate.
Dinutuximab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dinutuximab.
Diphenhydramine	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Diphenhydramine.
Dipyridamole	The risk or severity of bleeding can be increased when Dipyridamole is combined with Gemtuzumab ozogamicin.
Diroximel	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Diroximel fumarate.
Docetaxel	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Docetaxel.
Dostarlimab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dostarlimab.
Doxorubicin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Doxorubicin.
Drotrecogin alfa	The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Gemtuzumab ozogamicin.
Dulaglutide	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dulaglutide.
Dupilumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dupilumab.
Durvalumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Durvalumab.
Dyclonine	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Dyclonine.
Ebola Zaire	The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Eculizumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eculizumab.
Edetic acid	The risk or severity of bleeding can be increased when Edetic acid is combined with Gemtuzumab ozogamicin.
Edoxaban	The risk or severity of bleeding can be increased when Edoxaban is combined with Gemtuzumab ozogamicin.
Efalizumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Efalizumab.
Eflapegrastim	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eflapegrastim.
Eftrenonacog alfa	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eftrenonacog alfa.
Elotuzumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Elotuzumab.
Emapalumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Emapalumab.
Emicizumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Emicizumab.
Enoxaparin	The risk or severity of bleeding can be increased when Enoxaparin is combined with Gemtuzumab ozogamicin.
Epirubicin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Epirubicin.
Epoprostenol	The risk or severity of bleeding can be increased when Epoprostenol is combined with Gemtuzumab ozogamicin.
Eptifibatide	The risk or severity of bleeding can be increased when Eptifibatide is combined with Gemtuzumab ozogamicin.
Eptinezumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eptinezumab.
Erenumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Erenumab.
Eribulin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eribulin.
Erythropoietin	The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Gemtuzumab ozogamicin.
Esterified estrogens	Esterified estrogens may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Estetrol	Estetrol may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Estradiol	Estradiol may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Estradiol acetate	Estradiol acetate may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Estradiol benzoate	Estradiol benzoate may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Estradiol cypionate	Estradiol cypionate may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Estradiol valerate	Estradiol valerate may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Estramustine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Estramustine.
Estriol	Estriol may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Estrone	Estrone may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Estrone sulfate	Estrone sulfate may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Gemtuzumab ozogamicin.
Ethinylestradiol	Ethinylestradiol may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Ethyl chloride.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Etidocaine.
Etoposide	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Etoposide.
Everolimus	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Everolimus.
Evolocumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Evolocumab.

Famtozinameran	The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Gemtuzumab ozogamicin.
Fanolesomab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fanolesomab.
Filgotinib	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Filgotinib.
Fingolimod	Gemtuzumab ozogamicin may increase the immunosuppressive activities of Fingolimod.
Floxuridine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Floxuridine.
Flucytosine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Flucytosine.
Fludarabine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fludarabine.
Fludrocortisone	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fludrocortisone.
Fluindione	The risk or severity of bleeding can be increased when Fluindione is combined with Gemtuzumab ozogamicin.
Flunisolide	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Flunisolide.
Fluocinolone	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluocinolone acetonide.
Fluocinonide	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluocinonide.
Fluocortolone	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluocortolone.
Fluorometholone	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluorometholone.
Fluorouracil	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluorouracil.
Flupentixol	The risk or severity of myelosuppression can be increased when Flupentixol is combined with Gemtuzumab ozogamicin.
Fluprednisolone	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluprednisolone.
Fluticasone	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluticasone.
Fluticasone furoate	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluticasone furoate.
Fluticasone	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluticasone propionate.
Fondaparinux	The risk or severity of bleeding can be increased when Fondaparinux is combined with Gemtuzumab ozogamicin.
Fremanezumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fremanezumab.
Galcanezumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Galcanezumab.
Gallium nitrate	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gallium nitrate.
Gemcitabine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gemcitabine.
Glatiramer	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Glatiramer.
Golimumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Golimumab.
Guselkumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Guselkumab.
Haemophilus	The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Gemtuzumab ozogamicin.
Heparin	The risk or severity of bleeding can be increased when Heparin is combined with Gemtuzumab ozogamicin.
Hepatitis A	The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.
Hepatitis globulin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hepatitis B immune globulin.
Hepatitis B Vaccine	The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Gemtuzumab ozogamicin.
Human adenovirus	The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Gemtuzumab ozogamicin.
Human globulin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Human cytomegalovirus immune globulin.
immunoglobulin G	The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Gemtuzumab ozogamicin.
immune globulin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Human Rho(D) immune globulin.
Human varicella	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Human varicella-zoster immune globulin.
Hydrochlorothiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Gemtuzumab ozogamicin.
Hydrocortisone	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydrocortisone acetate.
Hydrocortisone	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydrocortisone butyrate.
Hydrocortisone	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydrocortisone succinate.
Hydroflumethiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Gemtuzumab ozogamicin.
Hydroxychloroquine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydroxychloroquine.
Hydroxyurea	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydroxyurea.
Ibalizumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibalizumab.
Ibritumomab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibritumomab tiuxetan.
Ibrutinib	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibrutinib.
Icosapent ethyl	The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Gemtuzumab ozogamicin.
Idarubicin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Idarubicin.
Idarucizumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Idarucizumab.
Idelalisib	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Idelalisib.
Ifosfamide	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ifosfamide.
Iloprost	The risk or severity of bleeding can be increased when Iloprost is combined with Gemtuzumab ozogamicin.
Imatinib	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Imatinib.
Imdevimab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Imdevimab.
Imlifidase	The therapeutic efficacy of Gemtuzumab ozogamicin can be decreased when used in combination with Imlifidase.
Indomethacin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Indomethacin.
Inebilizumab	The risk or severity of infection can be increased when Gemtuzumab ozogamicin is combined with Inebilizumab.
Infliximab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Infliximab.
Influenza A	The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Influenza A virus	The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Influenza	The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Gemtuzumab ozogamicin.
Influenza A virus	The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Influenza A virus A	The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Influenza A	The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Gemtuzumab ozogamicin.
Influenza A	The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Influenza A virus	The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Influenza A	The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Influenza B	The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Influenza B	The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Influenza B	The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Influenza B	The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Inotuzumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Inotuzumab ozogamicin.
Interferon alfa-2a	The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Gemtuzumab ozogamicin.
Interferon alfa-2b	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon alfa-2b.
Interferon alfa-n1	The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Gemtuzumab ozogamicin.
Interferon alfa-n3	The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Gemtuzumab ozogamicin.
Interferon	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon alfacon-1.
Interferon beta-1b	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon beta-1b.
Interferon gamm	The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Gemtuzumab ozogamicin.
Ipilimumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ipilimumab.
Irinotecan	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Irinotecan.
Isatuximab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Isatuximab.
Ixabepilone	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ixabepilone.
Ixekizumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ixekizumab.
COVID-19 Vaccine	The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.
Ja encephalitis	The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Lanadelumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lanadelumab.
Leflunomide	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Leflunomide.
Lenalidomide	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lenalidomide.
Lepirudin	The risk or severity of bleeding can be increased when Lepirudin is combined with Gemtuzumab ozogamicin.
Levobupivacaine	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Levobupivacaine.
Lidocaine	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Lidocaine.
Linezolid	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Linezolid.
Lipegfilgrastim	Gemtuzumab ozogamicin may increase the myelosuppressive activities of Lipegfilgrastim.
Lomustine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lomustine.
Loncastuximab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Loncastuximab tesirine.
Lopinavir	The serum concentration of Gemtuzumab ozogamicin can be increased when it is combined with Lopinavir.
Maftivimab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Maftivimab.

Magnesium	The serum concentration of Magnesium can be decreased when it is combined with Gemtuzumab ozogamicin.
Margetuximab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Margetuximab.
Measles virus	The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Gemtuzumab ozogamicin.
Mechlorethamine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mechlorethamine.
Meloxicam	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Meloxicam.
Melphalan	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Melphalan.
Meningococcal	The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.
Mepivacaine	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Mepivacaine.
Mepolizumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mepolizumab.
Meprednisone	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Meprednisone.
Mercaptopurine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mercaptopurine.
Mestranol	Mestranol may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Methimazole	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Methimazole.
Methotrexate	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Methotrexate.
Methoxy	The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Gemtuzumab ozogamicin.
Methylprednisolone	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Methylprednisolone.
Mirvetuximab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mirvetuximab Soravtansine.
Mitomycin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mitomycin.
Mitoxantrone	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mitoxantrone.
COVID-19 Vaccine	The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.
Modified v	The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Gemtuzumab ozogamicin.
Mogamulizumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mogamulizumab.
Mometasone	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mometasone furoate.
Monomethyl	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Monomethyl fumarate.
Mosunetuzumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mosunetuzumab.
Mumps virus n	The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Gemtuzumab ozogamicin.
Muromonab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Muromonab.
Mycophenolate	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mycophenolate mofetil.
Mycophenolic	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mycophenolic acid.
Nadroparin	The risk or severity of bleeding can be increased when Nadroparin is combined with Gemtuzumab ozogamicin.
Natalizumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Natalizumab.
Necitumumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Necitumumab.
Nelarabine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nelarabine.
Nilotinib	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nilotinib.
Nimesulide	The risk or severity of bleeding can be increased when Nimesulide is combined with Gemtuzumab ozogamicin.
Nivolumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nivolumab.
Nuvaxovid	The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Gemtuzumab ozogamicin.
Obiltoxaximab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Obiltoxaximab.
Obinutuzumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Obinutuzumab.
Ocrelizumab	Ocrelizumab may increase the immunosuppressive activities of Gemtuzumab ozogamicin.
Odesivimab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Odesivimab.
Ofatumumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ofatumumab.
Olaparib	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Olaparib.
Olaratumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Olaratumab.
Omalizumab	The risk or severity of adverse effects can be increased when Omalizumab is combined with Gemtuzumab ozogamicin.
Oxaliplatin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Oxaliplatin.
Oxetacaine	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Oxetacaine.
Oxybuprocaine	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Oxybuprocaine.
Ozanimod	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ozanimod.
Paclitaxel	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Paclitaxel.
Palbociclib	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Palbociclib.
Palifermin	The therapeutic efficacy of Palifermin can be decreased when used in combination with Gemtuzumab ozogamicin.
Palivizumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Palivizumab.
Panitumumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Panitumumab.
Panobinostat	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Panobinostat.
Parnaparin	The risk or severity of bleeding can be increased when Parnaparin is combined with Gemtuzumab ozogamicin.
Pazopanib	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pazopanib.
Pegaspargase	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pegaspargase.
Pegcetacoplan	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pegcetacoplan.
Peginesatide	The risk or severity of Thrombosis can be increased when Peginesatide is combined with Gemtuzumab ozogamicin.
Peginterferon	The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Gemtuzumab ozogamicin.
Peginterferon 2b	The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Gemtuzumab ozogamicin.
Peginterferon	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Peginterferon beta-1a.
Pembrolizumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pembrolizumab.
Pemetrexed	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pemetrexed.
Penicillamine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Penicillamine.
Pentosan p	The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Gemtuzumab ozogamicin.
Pentostatin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pentostatin.
Pentoxifylline	The risk or severity of bleeding can be increased when Pentoxifylline is combined with Gemtuzumab ozogamicin.
Pertussis vaccine	The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.
Pertuzumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pertuzumab.
Pexidartinib	Gemtuzumab ozogamicin may increase the hepatotoxic activities of Pexidartinib.
Phenindione	The risk or severity of bleeding can be increased when Phenindione is combined with Gemtuzumab ozogamicin.
Phenol	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Phenol.
Phenprocoumon	The risk or severity of bleeding can be increased when Phenprocoumon is combined with Gemtuzumab ozogamicin.
Phenylalanine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Phenylalanine.
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Gemtuzumab ozogamicin.
Pirfenidone	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pirfenidone.
Polatuzumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Polatuzumab vedotin.
Polyestradiol	Polyestradiol phosphate may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Polythiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Gemtuzumab ozogamicin.
Pomalidomide	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pomalidomide.
Ponatinib	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ponatinib.
Ponesimod	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ponesimod.
Pralatrexate	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pralatrexate.
Pramocaine	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Pramocaine.
Prasugrel	The risk or severity of bleeding can be increased when Prasugrel is combined with Gemtuzumab ozogamicin.
Prednisolone	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Prednisolone.
Prednisone	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Prednisone.
Prilocaine	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Prilocaine.
Procaine	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Procaine.
Procarbazine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Procarbazine.
Proparacaine	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Proparacaine.
Propoxycaine	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Propoxycaine.
Propylthiouracil	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Propylthiouracil.
Protein C	The risk or severity of bleeding can be increased when Protein C is combined with Gemtuzumab ozogamicin.
Protein S	The risk or severity of bleeding can be increased when Protein S human is combined with Gemtuzumab ozogamicin.
Quinestrol	Quinestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin.

Ramucirumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ramucirumab.
Ranibizumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ranibizumab.
Ravulizumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ravulizumab.
Raxibacumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Raxibacumab.
Reslizumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Reslizumab.
Reteplase	The risk or severity of bleeding can be increased when Reteplase is combined with Gemtuzumab ozogamicin.
Reviparin	The risk or severity of bleeding can be increased when Reviparin is combined with Gemtuzumab ozogamicin.
Rilonacept	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rilonacept.
Risankizumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Risankizumab.
Rituximab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rituximab.
Rivaroxaban	The risk or severity of bleeding can be increased when Rivaroxaban is combined with Gemtuzumab ozogamicin.
Roflumilast	Roflumilast may increase the immunosuppressive activities of Gemtuzumab ozogamicin.
Romosozumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Romosozumab.
Ropeginterferon	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ropeginterferon alfa-2b.
Ropivacaine	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Ropivacaine.
Rotavirus vaccine	The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.
Rubella virus vaccine	The risk or severity of infection can be increased when Rubella virus vaccine is combined with Gemtuzumab ozogamicin.
Ruxolitinib	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ruxolitinib.
Sacituzumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sacituzumab govitecan.
Sarilumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sarilumab.
Satralizumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Satralizumab.
Secukinumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Secukinumab.
Siltuximab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Siltuximab.
Siponimod	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Siponimod.
Sipuleucel-T	The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Gemtuzumab ozogamicin.
Sirolimus	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sirolimus.
Smallpox	The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Gemtuzumab ozogamicin.
Sodium citrate	The risk or severity of bleeding can be increased when Sodium citrate is combined with Gemtuzumab ozogamicin.
Sorafenib	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sorafenib.
Sotrovimab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sotrovimab.
Spesolimab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Spesolimab.
Streptokinase	The risk or severity of bleeding can be increased when Streptokinase is combined with Gemtuzumab ozogamicin.
Streptozocin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Streptozocin.
Sulesomab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sulesomab.
Sulfamethoxazole	The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Gemtuzumab ozogamicin.
Sulfasalazine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sulfasalazine.
Sulfinpyrazone	The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Gemtuzumab ozogamicin.
Sulodexide	The risk or severity of bleeding can be increased when Sulodexide is combined with Gemtuzumab ozogamicin.
Sunitinib	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sunitinib.
Sutimlimab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sutimlimab.
SyEstrogens, A	Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Gemtuzumab ozogamicin.
SEstrogens, B	Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Tacrolimus	Tacrolimus may increase the immunosuppressive activities of Gemtuzumab ozogamicin.
Tafasitamab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tafasitamab.
Tedizolid	The risk or severity of myelosuppression can be increased when Gemtuzumab ozogamicin is combined with Tedizolid phosphate.
Temozolomide	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Temozolomide.
Temsirolimus	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Temsirolimus.
Tenecteplase	The risk or severity of bleeding can be increased when Tenecteplase is combined with Gemtuzumab ozogamicin.
Teniposide	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teniposide.
Teplizumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teplizumab.
Teprotumumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teprotumumab.
Teriflunomide	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teriflunomide.
Tetanus	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tetanus immune globulin, human.
Tetracaine	The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Tetracaine.
Tezepelumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tezepelumab.
Thalidomide	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Thalidomide.
Thiotepa	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Thiotepa.
Tibolone	Tibolone may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Ticagrelor	The risk or severity of bleeding can be increased when Ticagrelor is combined with Gemtuzumab ozogamicin.
Tick-borne	The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
Ticlopidine	The risk or severity of bleeding can be increased when Ticlopidine is combined with Gemtuzumab ozogamicin.
Tildrakizumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tildrakizumab.
Tinzaparin	The risk or severity of bleeding can be increased when Tinzaparin is combined with Gemtuzumab ozogamicin.
Tioguanine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tioguanine.
Tirofiban	The risk or severity of bleeding can be increased when Tirofiban is combined with Gemtuzumab ozogamicin.
Tisotumab vedotin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tisotumab vedotin.
Tixagevimab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tixagevimab.
Tixocortol	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tixocortol.
Tocilizumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tocilizumab.
Tofacitinib	Gemtuzumab ozogamicin may increase the immunosuppressive activities of Tofacitinib.
Topotecan	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Topotecan.
Tositumomab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tositumomab.
Trabectedin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trabectedin.
Tralokinumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tralokinumab.
Trastuzumab	Trastuzumab may increase the neutropenic activities of Gemtuzumab ozogamicin.
Trastuzumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trastuzumab deruxtecan.
Trastuzumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trastuzumab emtansine.
Tremelimumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tremelimumab.
Tretinoin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tretinoin.
Triamcinolone	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Triamcinolone.
Trichlormethiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Gemtuzumab ozogamicin.
Trifluridine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trifluridine.
Triflusal	The risk or severity of bleeding can be increased when Triflusal is combined with Gemtuzumab ozogamicin.
Trilostane	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trilostane.
Typhoid vaccine	The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.
Typhoid Vaccine	The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Gemtuzumab ozogamicin.
Typhoid	The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.
Upadacitinib	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Upadacitinib.
Urokinase	The risk or severity of bleeding can be increased when Urokinase is combined with Gemtuzumab ozogamicin.
Ustekinumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ustekinumab.
Valoctocogene	The therapeutic efficacy of Valoctocogene roxaparvovec can be decreased when used in combination with Gemtuzumab ozogamicin.
Varicella zoster	The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Gemtuzumab ozogamicin.
Varicella zoster	The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Gemtuzumab ozogamicin.
Vedolizumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vedolizumab.
Vibrio cholerae	The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Gemtuzumab ozogamicin.
Vilanterol	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vilanterol.
Vinblastine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vinblastine.
Vincristine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vincristine.

Vindesine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vindesine.
Vinorelbine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vinorelbine.
Voclosporin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Voclosporin.
Vorapaxar	The risk or severity of bleeding can be increased when Vorapaxar is combined with Gemtuzumab ozogamicin.
Vorinostat	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vorinostat.
Warfarin	The risk or severity of bleeding can be increased when Warfarin is combined with Gemtuzumab ozogamicin.
Ximelagatran	The risk or severity of bleeding can be increased when Ximelagatran is combined with Gemtuzumab ozogamicin.
Yellow fever	The risk or severity of infection can be increased when Yellow fever vaccine is combined with Gemtuzumab ozogamicin.
Zidovudine	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Zidovudine.

Pregnancy and Lactation

US FDA pregnancy category Not Assigned

Pregnancy

Based on its mechanism of action and findings from animal studies [see Clinical Pharmacology (12.1) and Nonclinical Toxicology (13.1)], MYLOTARG can cause embryo-fetal harm when administered to a pregnant woman. There are no available data on MYLOTARG use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. In rat embryo-fetal development studies, gemtuzumab ozogamicin caused embryo-fetal toxicity at maternal systemic exposures that were greater than or equal to 0.4 times the
exposure in patients at the maximum recommended dose, based on AUC (see Data). If MYLOTARG is used during pregnancy, or if the patient becomes pregnant while taking MYLOTARG, advise the patient of the potential risk to a fetus.

Lactation

There are no data on the presence of gemtuzumab ozogamicin or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. Because of the potential for adverse reactions in breastfed infants, women should not breastfeed during treatment with MYLOTARG and for at least 1 month after the final dose.

How should this medicine be used?

Gemtuzumab ozogamicin injection comes as a powder to be mixed with liquid and given through a needle or catheter placed into a vein. It is usually injected slowly over a period of 2 hours. Your doctor will tell you how often you will receive gemtuzumab ozogamicin injection. The dosing schedule depends on if you are being treated with other chemotherapy medications, if your cancer was previously treated, and how your body responds to the medication.

Gemtuzumab ozogamicin injection may cause serious or life-threatening reactions during an infusion and for up to a day afterwards. You will receive certain medications to help prevent a reaction before you receive each dose of gemtuzumab ozogamicin. A doctor or nurse will watch you closely while you are receiving the infusion and shortly after the infusion to be sure you are not having a serious reaction to the medication. Tell your doctor or nurse immediately if you experience any of the following symptoms that may occur during or within 24 hours after the infusion: rash, fever, chills, fast heartbeat, swollen tongue or throat, shortness of breath or difficulty breathing.

Your doctor may slow down your infusion, delay, or stop your treatment with gemtuzumab ozogamicin injection, or treat you with additional medications depending on your response to the medication and any side effects that you experience. Talk to your doctor about how you are feeling during and after your treatment.

What special precautions should I follow?

Before receiving gemtuzumab ozogamicin injection,

• tell your doctor and pharmacist if you are allergic to gemtuzumab ozogamicin, any other medications, or any of the ingredients in gemtuzumab ozogamicin injection. Ask your pharmacist for a list of the ingredients.
• tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: amiodarone (Cordarone, Nexterone, Pacerone), anagrelide (Agrylin), chloroquine, chlorpromazine, cilostazol, citalopram (Celexa), disopyramide (Norpace), dofetilide (Tikosyn), donepezil (Aricept, in Namzaric), dronedarone (Multaq), escitalopram (Lexapro), flecainide (Tambocor), fluconazole (Diflucan), haloperidol (Haldol), ibutilide (Corvert), methadone (Methadose, Dolophine), ondansetron (Zuplenz, Sofran), pimozide (Orap), procainamide, quinidine (in Nuedexta), sotalol (Betapace, Sorine, Sotylize), and thioridazine. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with gemtuzumab ozogamicin injection, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
• tell your doctor if you or anyone in your family has or has ever had long QT syndrome (condition that increases the risk of developing an irregular heartbeat that may cause fainting or sudden death), or if you have or have ever had or higher or lower than normal levels of sodium, potassium, calcium, or magnesium in your blood.
• tell your doctor if you are pregnant, plan to become pregnant, or plan to father a child. You should not become pregnant while you are receiving gemtuzumab ozogamicin injection. You will need to have a negative pregnancy test before you begin receiving this medication. Use effective birth control during your treatment with gemtuzumab ozogamicin injection and for 6 months after your final dose. If you are a male and your partner can become pregnant, you should use effective birth control during your treatment and for 3 months after your final dose. If you or your partner become pregnant while receiving gemtuzumab ozogamicin injection, call your doctor.
• tell your doctor if you are breastfeeding. You should not breastfeed while you are receiving gemtuzumab ozogamicin injection, and for 1 month after your final dose.
• you should know that this medication may decrease fertility in men and women. Talk to your doctor about the risks of receiving gemtuzumab ozogamicin.

References

Show More